A new study by the NYU Cancer Institute, an NCI-designated cancer center, sheds light on the origins of a type of myeloid leukemia, a blood cancer that affects children and adults. The researchers discovered that novel mutations in an intracellular communication pathway called Notch led to the cancer, pointing to a potential new target for treating this disease. Notch has already been implicated in another type of blood cancer called T-cell acute lymphoblastic leukemia, but the new research found an unexpected role for it in chronic myelomonocytic leukemia (CMML). The study is published in the May 12, 2011 issue of the journal Nature.
"This study shows the power of the Notch signaling pathway in myeloid leukemias," says Iannis Aifantis, PhD, associate professor in the Department of Pathology at NYU Langone Medical Center and a member of the NYU Cancer Institute, who led the new study. "This discovery," he says, "suggests a potential for future targeted therapies." Dr. Aifantis is also a Howard Hughes Medical Institute Early Career Scientist.
CMML is a type of myeloid leukemia. Normally, the bone marrow makes blood stem cells (immature) that mature over time. Some of these are a form called myeloid and others are lymphoid. The lymphoid stem cell develops into a white blood cell, while the more-versatile myeloid stem cell develops into red blood cells, white blood cells, and platelets, which prevent clotting. Cancer occurs when too many immature myeloid stem cells are produced in the blood and bone marrow.
The Notch signaling pathway, the complex web of intracellular interactions that occurs after a protein called Notch is activated on the cell's surface, is a well known actor in cancer, but the new study reveals that the varied members of this pathway function in unexpected ways to produce disease. Notch is named for a particular kind of mutation, first identified almost 100 years ago, that gives fruit flies notched wings.
The study evaluated mutations in the Notch pathway in mice models of the disease, and also in blood samples from patients with chronic myelomonocytic leukemia. Researchers identified several mutations that inactivated or silenced the pathway, leading to the accelerated accumulation of abnormal blood cells. Most importantly, the study also revealed that the reactivation of the silenced genes in the pathway blocked the disease, providing additional support for the potentially crucial role that Notch might play in the development of cancer.
In a commentary accompanying the study in Nature, Demetrios Kalaitzidis and Scott A. Armstrong of Dana Farber Cancer Institute and Children's Hospital Boston, note that the study defines a new role for Notch signaling as a suppressor of leukemia development. They note that further research is needed to understand the intricacies of Notch signaling in normal and cancerous tissue, which will help determine "the best approaches to manipulating this pathway for optimal therapauetic response."
This research study was funded by the Howard Hughes Medical Institute.
About the NYU Cancer Institute
The NYU Cancer Institute is an NCI-designated cancer center. Its mission is to discover the origins of human cancer and to use that knowledge to eradicate the personal and societal burden of cancer in our community, the nation and the world. The center and its multidisciplinary team of experts provide access to the latest treatment options and clinical trials along with a variety of programs in cancer prevention, screening, diagnostics, genetic counseling and supportive services. For additional information, please visit: www.nyuci.org.
About NYU Langone Medical Center
NYU Langone Medical Center, a world-class patient-centered integrated academic medical center, is one of the nation's premier centers for excellence in health care, biomedical research, and medical education. Located in the heart of Manhattan, NYU Langone is comprised of three hospitals-Tisch Hospital, a 705-bed acute-care tertiary facility, Rusk Institute of Rehabilitation Medicine, the first rehabilitation hospital in the world, with 174 beds and extensive outpatient rehabilitation programs, and the 190-bed Hospital for Joint Diseases, one of only five hospitals in the world dedicated to orthopaedics and rheumatology-plus the NYU School of Medicine, one of the nation's preeminent academic institutions. For more information, visit http://www.